GlassScriptPhysician profile
Tristan Bice
NPI 1912369190
$3,624.07
in general payments reported to CMS, 2019-2025
26 companies · $900 in 2025
The $900 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347 · 2022: $421 · 2023: $1,192 · 2024: $764 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921 · Education: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.28 |
| Education | $934.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $947.59 | 2021-2025 | Vyloy |
| Sanofi-Aventis U.S. LLC | $266.74 | 2023-2025 | |
| Seagen INC. | $234.28 | 2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $228.61 | 2024-2025 | Datroway, Imfinzi |
| Boston Scientific Corporation | $159.70 | 2024 | Spaceoar Vue System - 10ml, Spaceoar System |
| Exelixis INC. | $156.62 | 2022 | |
| Syndax Pharmaceuticals, INC. | $141.93 | 2025 | Revuforj |
| Ipsen Biopharmaceuticals, INC | $137.03 | 2023 | Tazverik, Onivyde |
| E.R. Squibb & Sons, L.L.C. | $131.25 | 2024 | |
| Cti Biopharma Corp. | $130.71 | 2023 | Vonjo |
| Incyte Corporation | $125.01 | 2023 | Jakafi |
| Foundation Medicine, INC. | $122.25 | 2023 | |
| Stemline Therapeutics INC. | $120.00 | 2023 | Orserdu |
| Adc Therapeutics America, INC. | $118.80 | 2025 | |
| Beigene USA, INC. | $108.86 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106.41 | 2025 | |
| Janssen Biotech, INC. | $99.95 | 2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $89.99 | 2024-2025 | |
| Gilead Sciences, INC. | $83.99 | 2022 | |
| Blueprint Medicines Corporation | $71.44 | 2022 | |
| Myriad Genetic Laboratories, INC. | $24.82 | 2025 | Myrisk |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Keytruda |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tristan Bice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.